Subscribe: pubmed: BMT[Jour]
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0rkpg7psB96kXSn8rHgLXj86RUVpfN48_gOyRQErBE5
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
agvhd  bone loss  bone marrow  bone  cell transplantation  loss  marrow  risk adapted  severe  stem cell  transplant  transplantation 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: pubmed: BMT[Jour]

pubmed: BMT[Jour]



NCBI: db=pubmed; Term="Bone marrow transplantation"[Jour]



 



Against the odds: haplo-cord grafts protect from GvHD and relapse.
Related Articles

Against the odds: haplo-cord grafts protect from GvHD and relapse.

Bone Marrow Transplant. 2017 Jun 19;:

Authors: Choe HK, van Besien K

PMID: 28628090 [PubMed - as supplied by publisher]




Elevated bone marrow eosinophil count is associated with high incidence of severe acute GvHD after allogeneic hematopoietic stem cell transplantation.
Related Articles

Elevated bone marrow eosinophil count is associated with high incidence of severe acute GvHD after allogeneic hematopoietic stem cell transplantation.

Bone Marrow Transplant. 2017 Jun 19;:

Authors: Shimomura Y, Hara M, Hashimoto H, Ishikawa T

Abstract
Predicting severe acute GvHD (aGvHD) after allogeneic hematopoietic stem cell transplantation (HSCT) is challenging but critical. Mild aGvHD may have a favorable impact on relapse, whereas severe aGvHD is associated with poor outcomes. The aim of this study was to evaluate whether elevated eosinophil count in the bone marrow (BM) at 1 month after HSCT is associated with a high incidence of new and severe aGvHD. We enrolled 101 consecutive patients; median age was 50 years, and 50.5% patients were male. The median eosinophil concentration in BM at 1 month after HSCT was 1.1% (quartile 0.4-2.2%). The adjusted hazards ratio at 95% confidence interval for severe aGvHD was 1.26 (1.12-1.42, P<0.001), per 1% increase in eosinophil concentration, and 3.76 (1.41-10.05, P=0.008) for the high-risk group at a cutoff value of 4.0%. In addition, the predictive accuracy described by area under the curve of receiver operating characteristics, increased from 0.784 to 0.866 (P=0.033) with the increasing concentration of eosinophils. In conclusion, elevated concentration of eosinophils in BM was associated with high incidence and predictive accuracy of severe aGvHD. BM eosinophil concentration can be one of the key markers to predict aGvHD.Bone Marrow Transplantation advance online publication, 19 June 2017; doi:10.1038/bmt.2017.98.

PMID: 28628089 [PubMed - as supplied by publisher]




An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial.
Related Articles

An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial.

Bone Marrow Transplant. 2017 Jun 19;:

Authors: Grigg A, Butcher B, Khodr B, Bajel A, Hertzberg M, Patil S, D'Souza AB, Ganly P, Ebeling P, Wong E

Abstract
Bone loss occurs frequently following allogeneic haematopoietic stem cell transplantation (alloSCT). The Australasian Leukaemia and Lymphoma Group conducted a prospective phase II study of pretransplant zoledronic acid (ZA) and individualised post-transplant ZA to prevent bone loss in alloSCT recipients. Patients received ZA 4 mg before conditioning. Administration of post-transplant ZA from days 100 to 365 post alloSCT was determined by a risk-adapted algorithm based on serial bone density assessments and glucocorticoid exposure. Of 82 patients enrolled, 70 were alive and without relapse at day 100. A single pretransplant dose of ZA prevented femoral neck bone loss at day 100 compared with baseline (mean change -2.6±4.6%). Using the risk-adapted protocol, 42 patients received ZA between days 100 and 365 post alloSCT, and this minimised bone loss at day 365 compared with pretransplant levels (mean change -2.9±5.3%). Femoral neck bone loss was significantly reduced in ZA-treated patients compared with historical untreated controls at days 100 and 365. This study demonstrates that a single dose of ZA pre-alloSCT prevents femoral neck bone loss at day 100 post alloSCT, and that a risk-adapted algorithm is able to guide ZA administration from days 100 to 365 post transplant and minimise further bone loss.Bone Marrow Transplantation advance online publication, 19 June 2017; doi:10.1038/bmt.2017.108.

PMID: 28628088 [PubMed - as supplied by publisher]